[Pilot studies on the treatment of Mycobacterium avium complex lung disease--new macrolides and new quinolones. (2) Multi-drug chemotherapy for initial cases on trial].
Tanaka
E
E
Department of Infection and Inflammation, Chest Disease Research Institute, Kyoto University.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage*; D000995:Antitubercular Agents / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage; D006801:Humans; D007612:Kanamycin / Q000008:administration & dosage; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D015242:Ofloxacin / Q000008:administration & dosage*; D010865:Pilot Projects; D012293:Rifampin / Q000008:administration & dosage; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D007612:Kanamycin; D004977:Ethambutol; D015242:Ofloxacin; D017291:Clarithromycin; D012293:Rifampin